TY  - GEN
AU  - van Hout,B A
AU  - Bowman,L
AU  - Zelinger,D J
AU  - Simoons,M L
TI  - Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications
SN  - 0002-8703
PY  - 1998///0424
KW  - Abciximab
KW  - Acute Disease
KW  - Angioplasty, Balloon, Coronary
KW  - Antibodies, Monoclonal
KW  - economics
KW  - Coronary Disease
KW  - Cost-Benefit Analysis
KW  - Dose-Response Relationship, Drug
KW  - Double-Blind Method
KW  - Follow-Up Studies
KW  - Humans
KW  - Immunoglobulin Fab Fragments
KW  - Infusions, Intravenous
KW  - Platelet Aggregation Inhibitors
KW  - Prospective Studies
KW  - Risk Factors
KW  - Treatment Outcome
KW  - United States
N1  - Publication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1016/s0002-8703(98)70302-3
ER  -